TCI Biotech Reports Impressive Financial Results for 2024 and Plans Global Expansion
On March 10, 2025, TCI Biotech (TCI Co., Ltd.), listed on the Taiwan Stock Exchange under the ticker TWSE: 8436, unveiled its consolidated financial results for the fiscal year that ended on December 31, 2024. The company demonstrated impressive financial stability, highlighting solid revenue figures, robust profitability, and ongoing commitments to innovation—hallmarks of TCI Biotech's operational strategy in the fields of health foods and skincare biotechnology.
CEO Vincent Lin detailed the financial performance by stating, "Our 2024 financial performance underscores TCI Biotech's resilience and ability to navigate market fluctuations while maintaining strong profitability." This statement reflects the company's commitment to enhancing its capabilities through smart manufacturing, strategic partnerships, and advanced research—essential elements for future growth and sustainability.
TCI Biotech's ongoing expansion into international markets has yielded considerable sales growth across regions such as North America, Europe, China, and Asia. This strategic drive not only amplifies its global presence but also fortifies TCI’s market position against competitors in the biotechnology sector.
The company has also made significant strides in research and development, particularly in liquid supplements and skincare products tailored to meet evolving market demands. As part of this initiative, TCI established the TCI Medical Consultation Panel, focusing on ensuring scientific rigor in research efforts.
In terms of operational efficiency, TCI Biotech has implemented strategic cost management practices alongside AI-enhanced production processes. These measures have played a crucial role in maintaining profitability despite the potential challenges faced by the industry worldwide.
Furthermore, the company is deeply committed to sustainability, evidenced by its continuous investment in ESG (Environmental, Social, and Governance) initiatives. By doing so, TCI Biotech aims to enhance its corporate responsibility and contribute to long-term value creation for all stakeholders.
Looking ahead, TCI Biotech is optimistic about its growth prospects for 2025. The company is focusing on achieving balanced regional expansion, optimizing production capacity, and forming strategic partnerships with leading global enterprises. This approach is expected to bolster its ongoing efforts in delivering high-quality, innovative products while reinforcing its market leadership in biotechnology and smart manufacturing.
The company remains dedicated to quality, innovation, and customer-oriented solutions, ensuring that its trajectory continues to reflect sustained revenue and profitability growth. With a clear vision for the future, TCI Biotech is poised to take significant strides in establishing itself as a leader in the biotechnology sector.
For more details, interested parties can visit TCI Biotech's official website at www.tci-bio.com. Throughout its journey, TCI Biotech will continue to embrace innovation and commitment to excellence, creating impactful solutions for the health and wellness sector worldwide.
TCI Biotech (TCI Co., Ltd.) stands as a global leader in providing CDMO+ services, focusing on the research, development, and manufacturing of health foods and cosmetics. With a resolute commitment to innovation and scientific excellence, TCI delivers clinically validated products that empower customers across the globe.
The statements in this release contain forward-looking statements based on current expectations and assumptions, associated with various risks and uncertainties. Actual results may diverge significantly due to market conditions, regulatory changes, or unforeseen circumstances. TCI Biotech does not commit to updating these forward-looking statements. Investors are encouraged to consult the full financial report and speak with professional advisors prior to making investment decisions.
CEO Vincent Lin detailed the financial performance by stating, "Our 2024 financial performance underscores TCI Biotech's resilience and ability to navigate market fluctuations while maintaining strong profitability." This statement reflects the company's commitment to enhancing its capabilities through smart manufacturing, strategic partnerships, and advanced research—essential elements for future growth and sustainability.
Financial Highlights
- - Revenue: NT$7.24 billion
- - Gross Profit: NT$3.18 billion, with a gross margin of 44%.
- - Operating Profit: NT$1.03 billion, sustaining a stable operating margin of 14%.
- - Net Profit: NT$974 million, amounting to an earnings per share (EPS) of NT$7.60.
- - Dividend: NT$10 per share, reflecting the company’s strong overall financial health.
- - Cash & Cash Equivalents: NT$4.77 billion, securing the company's liquidity in a competitive marketplace.
Key Business Developments
TCI Biotech's ongoing expansion into international markets has yielded considerable sales growth across regions such as North America, Europe, China, and Asia. This strategic drive not only amplifies its global presence but also fortifies TCI’s market position against competitors in the biotechnology sector.
The company has also made significant strides in research and development, particularly in liquid supplements and skincare products tailored to meet evolving market demands. As part of this initiative, TCI established the TCI Medical Consultation Panel, focusing on ensuring scientific rigor in research efforts.
In terms of operational efficiency, TCI Biotech has implemented strategic cost management practices alongside AI-enhanced production processes. These measures have played a crucial role in maintaining profitability despite the potential challenges faced by the industry worldwide.
Furthermore, the company is deeply committed to sustainability, evidenced by its continuous investment in ESG (Environmental, Social, and Governance) initiatives. By doing so, TCI Biotech aims to enhance its corporate responsibility and contribute to long-term value creation for all stakeholders.
Outlook for 2025
Looking ahead, TCI Biotech is optimistic about its growth prospects for 2025. The company is focusing on achieving balanced regional expansion, optimizing production capacity, and forming strategic partnerships with leading global enterprises. This approach is expected to bolster its ongoing efforts in delivering high-quality, innovative products while reinforcing its market leadership in biotechnology and smart manufacturing.
The company remains dedicated to quality, innovation, and customer-oriented solutions, ensuring that its trajectory continues to reflect sustained revenue and profitability growth. With a clear vision for the future, TCI Biotech is poised to take significant strides in establishing itself as a leader in the biotechnology sector.
For more details, interested parties can visit TCI Biotech's official website at www.tci-bio.com. Throughout its journey, TCI Biotech will continue to embrace innovation and commitment to excellence, creating impactful solutions for the health and wellness sector worldwide.
About TCI Biotech
TCI Biotech (TCI Co., Ltd.) stands as a global leader in providing CDMO+ services, focusing on the research, development, and manufacturing of health foods and cosmetics. With a resolute commitment to innovation and scientific excellence, TCI delivers clinically validated products that empower customers across the globe.
Disclaimer
The statements in this release contain forward-looking statements based on current expectations and assumptions, associated with various risks and uncertainties. Actual results may diverge significantly due to market conditions, regulatory changes, or unforeseen circumstances. TCI Biotech does not commit to updating these forward-looking statements. Investors are encouraged to consult the full financial report and speak with professional advisors prior to making investment decisions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.